<DOC>
	<DOC>NCT00496028</DOC>
	<brief_summary>This study will comprise 2 parts, a dose escalation phase and a dose expansion phase. The 2 phases are part of a single study and described by this single protocol. Patients entered into the dose escalation phase will not be entered into the expansion phase. All subjects must be suitable for treatment with either carboplatin and/or paclitaxel.</brief_summary>
	<brief_title>Phase I Study in Patients With Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Saracatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Life expectancy &gt; 12 weeks Women defined as postmenopausal Male or female patients with locally advanced or metastatic cancer suitable for treatment with carboplatin and/or paclitaxel Inadequate bone marrow reserve Inadequate live function, renal function or low haemoglobin Unresolved toxicity from anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Solid tumors</keyword>
	<keyword>locally advanced or Metastatic Cancer suitable for treatment with carboplatin and/or paclitaxel</keyword>
</DOC>